A novel strategy was developed by combining 2 therapeutic approaches mediated by CRISPR/Cas9; deletion of HBA2 gene to recreate α-thalassemia trait with reduced α-globin production and integration of β-globin transgene downstream the HBA2 promoter to increase β-globin expression. The gene discussed is HBA2; the disease is thalassemia.